Corcept Therapeutics Incorporated
General ticker "CORT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $7.1B (TTM average)
Corcept Therapeutics Incorporated follows the US Stock Market performance with the rate: 18.2%.
Estimated limits based on current volatility of 1.3%: low 35.48$, high 37.38$
Factors to consider:
- Total employees count: 500 (+42.0%) as of 2024
- Top business risk factors: Pandemic risks, Insufficient funding, Labor/talent shortage/retention, Regulatory and compliance, Political instability
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [35.84$, 61.61$]
- 2025-12-31 to 2026-12-31 estimated range: [30.21$, 53.81$]
Financial Metrics affecting the CORT estimates:
- Negative: with PPE of 41.7 at the end of fiscal year the price was high
- Positive: Operating profit margin, % of 20.29 > 18.33
- Positive: Shareholder equity ratio, % of 80.85 > 64.17
- Positive: Return on assets ratio (scaled to [-100,100]) of 14.38 > 6.04
- Positive: Inventory ratio change, % of 0.23 <= 0.82
- Negative: negative Industry operating cash flow (median)
- Positive: 0.04 < Operating cash flow per share per price, % of 3.71
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: -4.41 < Investing cash flow per share per price, % of -3.33
Short-term CORT quotes
Long-term CORT plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $401.86MM | $482.38MM | $675.04MM |
| Operating Expenses | $289.22MM | $375.09MM | $538.09MM |
| Operating Income | $112.63MM | $107.28MM | $136.95MM |
| Non-Operating Income | $3.56MM | $17.27MM | $24.54MM |
| R&D Expense | $130.99MM | $184.35MM | $246.89MM |
| Income(Loss) | $116.19MM | $124.56MM | $161.49MM |
| Taxes | $14.77MM | $18.42MM | $20.28MM |
| Profit(Loss)* | $101.42MM | $106.14MM | $139.73MM |
| Stockholders Equity | $501.84MM | $506.70MM | $679.59MM |
| Inventory | $6.10MM | $7.73MM | $12.41MM |
| Assets | $583.43MM | $621.52MM | $840.55MM |
| Operating Cash Flow | $120.32MM | $127.04MM | $198.07MM |
| Capital expenditure | $0.41MM | $0.14MM | $2.17MM |
| Investing Cash Flow | $-114.33MM | $90.91MM | $-177.60MM |
| Financing Cash Flow | $-17.28MM | $-148.72MM | $-28.35MM |
| Earnings Per Share** | $0.95 | $1.02 | $1.35 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.